Using a new drug to target cancer growth in head and neck tumors
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
This study is looking at a new drug called SVC112 to see how it can help treat head and neck cancers by making current treatments like radiation and immunotherapy work better, while also trying to protect healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10915632 on NIH RePORTER |
What this research studies
This research investigates the effects of a new drug called SVC112, which inhibits a specific protein involved in cancer cell growth, on head and neck squamous cell cancers (HNSCC). The study aims to understand how SVC112 can enhance the effectiveness of existing treatments like radiation therapy and immunotherapy. By focusing on the tumor microenvironment and using patient-derived models, the research seeks to identify how this drug can selectively target cancer cells while sparing normal cells. The approach includes both laboratory experiments and tests in animal models to evaluate the drug's potential in reducing tumor growth and improving treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma, especially those who have not responded to standard treatments.
Not a fit: Patients with other types of cancers or those who have not been diagnosed with head and neck squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with head and neck cancers, particularly those who do not respond well to current therapies.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting protein synthesis in cancer cells, indicating potential for success in this novel application.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Jimeno, Antonio — University of Colorado Denver
- Study coordinator: Jimeno, Antonio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.